Viatris Hikes Guidance With The Wind On Its Back At Halfway Stage
Low-End Guidance Jumps From $17.2bn To $17.5bn Total For 2021
Viatris enjoyed another strong quarter, its second full quarter as a combined entity, allowing for a raise in guidance across the board. Management discussed the firm’s strengths, and weaknesses, during the Q2 earnings call.
You may also be interested in...
As CEO Michael Goettler provides an update on the progress made by Viatris in its first year as a combined company, he also offers Generics Bulletin hints as to the detailed strategy that will be unveiled at the firm’s upcoming investor day and explains how biosimilars – including interchangeable Semglee (insulin glargine) – and complex generics are important components of the firm’s future growth plans.
Viatris will host another investor day, to take place early in the new year, to discuss its 2022-23 and 2024+ plans. Management provided details during the company’s Q3 earnings call, as Viatris announced it was once again raising full-year financial targets.
In November, ANI Pharmaceuticals is hoping to complete a major acquisition, Viatris may shed further light on the state of the US generics industry and Generics Bulletin will host its eighth annual Global Generics & Biosimilars Awards, this year once again in person.